EBEduardo Enrique Piñeyro Beltrán

Eduardo Enrique Piñeyro Beltrán

*This is an algorithmically generated author record based on publicly available information.

Eduardo Enrique Piñeyro Beltrán has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Super-Responder Case with Asthma, Chronic Rhinosinusitis and Nasal Polyposis Successfully Treated with Benralizumab

    by Piñeyro- Beltrán, Eduardo Enrique

    BACKGROUND: Benralizumab is a humanized, afucosylated anti-eosinophil monoclonal antibody that binds with high affinity and specificity to the alpha subunit of the human interleukin 5 receptor (IL-5Rα). Benralizumab is primarily indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma. This monoclonal antibody is increasingly recognized with a therapeutic effect in other entities in which activated eosinophils and basophils have a pivotal role in disease course. CASE REPORT: We herein report a case with nasal polyposis and asthma who was treated with benralizumab with an excellent response, characterized by absence of asthma crisis or rhinosinusitis, without the need of oral steroids, and with a low dose of inhaled medications. CONCLUSION: In conclusion, this case suggests that benralizumab may be considered earlier as a remission induction therapy in patients with asthma and other allergic comorbidities.

  • Open Access

    Diagnosis and Management of Hereditary Angioedema in Latin America: International Recommendations and Regional Practice Realities

    by Guillermo Arturo Guidos Fogelbach, Andrea Aida Velasco Medina, Freya Helena Campos Romero, Nora Alarcón, Antonio Albarrán Godínez, Mariana Bonifacino, Oscar Calderón, Iván Cherrez Ojeda, Herberto Chong Neto, Gonzalo Chorzepa, et al.

    Background: Current international hereditary angioedema (HAE) guidelines and treat-to-target recommendations consistently emphasize accurate diagnosis, early on-demand treatment of attacks, appropriate short-term prophylaxis for procedures, individualized long-term prophylaxis (LTP), and routine assessment of disease control and quality of life. Published information on how these recommendations are implemented in Latin America remains limited. We therefore aimed to assess the extent to which a Latin American expert panel converges with recommendations across current international HAE guidelines and consensus documents and to identify the principal barriers affecting real-world implementation in the region. Methods: A scientific committee developed and externally validated a 74-item questionnaire (domains summarized in Supplementary Table S1) and conducted a 2-round Delphi process among Latin American HAE experts. Consensus items were rated on a 9-point agreement scale, with consensus defined a priori as at least two-thirds of panelists scoring within a 3-point band in the agreement (7-9) or disagreement (1-3) range. Descriptive items captured expert-reported diagnostic testing, acute and preventive treatment patterns, monitoring practices, and implementation determinants using 5-point Likert scales. Instrument validation (July-November 2024) demonstrated high inter-rater agreement (Kendall W = 0.84; p < 0.001) and excellent internal consistency (Cronbach alpha = 0.92). Results: Thirty experts from 10 countries completed the process (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, Uruguay, Venezuela). Panel consensus broadly converged with recommendations across current international HAE guidelines and consensus documents on core diagnostic work-up (C4 plus C1-INH antigen and function; 84% consensus), selective use of genetics (97% consensus), first-line targeted LTP (pdC1-INH, Lanadelumab, Berotralstat; 94% consensus), retention of on-demand therapy for breakthrough attacks and for patients without access to LTP, routine monitoring, and management in special populations. The principal novel finding was an implementation feasibility gap: frequent or constant interruptions in prophylaxis supply were reported by 19/30 experts (63%), including 13/23 (57%) practicing in settings where public or insurance coverage was reported. Across the panel, cost (19/30; 63%) and medicine availability (8/30; 27%) were the most commonly cited barriers, with additional constraints related to diagnostic testing access and administrative pathways. Conclusions: Latin American expert consensus largely converges with recommendations across current international HAE guidelines and consensus documents on diagnosis, acute management, prophylaxis selection, monitoring, and special-population care. The dominant divergence is not clinical disagreement but implementation feasibility—particularly access to diagnostic testing, financing mechanisms, medicine availability, and continuity of supply. These findings provide region-specific evidence to contextualize international recommendations and support implementation strategies tailored to Latin America.

  • Open Access

    Consenso de expertos mexicanos acerca de la profilaxis a largo plazo en pacientes con angioedema hereditario en México

    by Guillermo Arturo Guidos Fogelbach, Andrea Aida Velasco Medina, Freya Helena Campos Romero, María Isabel Rojo Gutiérrez, Sandra Agustina Nieto Martínez, Ileana María Madrigal Beas, José Jesús López Tiro, Antonio Albarrán Godínez, Maria Eugenia Vargas Camaño, Juan José Matta Campos, et al.

    ANTECEDENTES: El angioedema hereditario es una enfermedad genética rara y potencialmente mortal, caracterizada por episodios recurrentes de edema subcutáneo y submucosa mediado por bradicinina, con impacto sustancial en la morbilidad, la calidad de vida y el uso de recursos sanitarios. La incorporación de nuevas terapias dirigidas ha modificado el paradigma de la profilaxis de largo plazo; sin embargo, su implementación depende de condiciones clínicas y, de forma crítica, determinantes estructurales y de acceso, propios del sistema de salud. OBJETIVO: Caracterizar de manera integral el tratamiento profiláctico del angioedema hereditario en México, con énfasis en el diagnóstico, la profilaxis a largo plazo, el acceso y la disponibilidad terapéutica, la percepción del control de la enfermedad y la aplicabilidad de recomendaciones clínicas, a partir de la opinión estructurada de especialistas nacionales. MÉTODOS: Análisis descriptivo y analítico de los datos correspondientes a México obtenidos mediante un ejercicio Delphi estructurado, con especialistas con experiencia en el tratamiento de angioedema hereditario. Se evaluaron las prácticas de diagnóstico, el proceso de selección y prescripción de terapias profilácticas, tratamientos poco recomendados, problemas de disponibilidad y acceso, y percepción clínica del control de la enfermedad y la aplicabilidad de guías internacionales. RESULTADOS: Los especialistas reportaron una alta alineación conceptual con las recomendaciones clínicas vigentes. La profilaxis a largo plazo se centró predominantemente en lanadelumab, con uso limitado de concentrados de C1-INH y ausencia de berotralstat. Aunque el sistema de salud público otorga cobertura del tratamiento, persisten las barreras relacionadas con disponibilidad y costos, lo que condicionó el acceso efectivo y la continuidad terapéutica. Las guías clínicas fueron consideradas altamente aplicables; no obstante, se identificó una brecha entre el tratamiento recomendado y el factible en la práctica cotidiana. CONCLUSIONES: El tratamiento profiláctico de pacientes con angioedema hereditario en México refleja avances clínicos relevantes y un enfoque alineado con estándares contemporáneos; sin embargo, persisten limitaciones estructurales que restringen la implementación sostenida e individualizada de la profilaxis. Entre las áreas prioritarias se incluyen el fortalecimiento del diagnóstico oportuno, el aseguramiento del acceso continuo a terapias dirigidas y la estandarización del seguimiento clínico. PALABRAS CLAVE: Angioedema hereditario; Morbilidad; Calidad de vida; Atención médica; Opinión de expertos; Profilaxis a largo plazo; Inhibidor de C1; Lanadelumab; Berotralstat; México.